HQL
Abrdn Life Sciences Investors·NYSE
--
--(--)
--
--(--)
HQL fundamentals
During FY 2025, Abrdn Life Sciences Investors (HQL) reported revenue of 1.94M, a YoY change of -51.30%. Net income was 85.59M, a YoY change of 0.35%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Oct 1, 2019 | Oct 1, 2019 | Oct 1, 2020 | Oct 1, 2020 | Oct 1, 2021 | Oct 1, 2021 | Oct 1, 2022 | Oct 1, 2022 | Oct 1, 2023 | Oct 1, 2023 | Oct 1, 2024 | Oct 1, 2024 | -- |
End Date | Mar 31, 2020 | Sep 30, 2020 | Mar 31, 2021 | Sep 30, 2021 | Mar 31, 2022 | Sep 30, 2022 | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | -- |
Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.50M -- | 2.07M -- | 3.98M +13.75% | -- -- | 1.94M -51.30% | 1.94M -- |
Operating Expenses | 2.64M -- | 5.51M -- | 3.13M +18.38% | 6.43M +16.69% | 3.12M -0.20% | 6.01M -6.48% | 2.87M -8.11% | 5.67M -5.57% | 2.72M -5.28% | 5.90M +3.98% | 2.74M +0.68% | 5.31M -9.95% | 5.31M -- |
Selling, General and Administrative Expenses | 2.37M -- | 4.99M -- | 2.86M +20.39% | 5.86M +17.46% | 2.80M -1.97% | 5.43M -7.35% | 2.62M -6.57% | 5.13M -5.45% | 2.31M -11.74% | 4.89M -4.66% | 2.41M +4.34% | 4.68M -4.28% | 4.68M -- |
Other Operating Expenses | 270.14K -- | 517.90K -- | 271.98K +0.68% | 566.16K +9.32% | 321.88K +18.35% | 580.42K +2.52% | 252.76K -21.48% | 541.44K -6.72% | 408.73K +61.71% | 1.01M +85.94% | 326.92K -20.01% | 629.25K -37.50% | 629.25K -- |
Operating Income | 30.19M -- | 123.05M -- | 31.55M +4.49% | 64.53M -47.56% | -76.30M -341.85% | -104.60M -262.10% | 33.80M +144.30% | 22.35M +121.37% | 50.26M +48.67% | 85.30M +281.60% | -47.23M -193.99% | 85.59M +0.35% | 85.59M -- |
Gain (Loss) on Change in Fair Value | 10.26M -- | 89.50M -- | 5.65M -44.92% | 25.94M -71.02% | -83.35M -1574.66% | -130.46M -602.93% | 26.85M +132.22% | -11.36M +91.29% | 53.20M +98.13% | 55.26M +586.57% | -62.70M -217.85% | 61.08M +10.52% | 61.08M -- |
Gain (Loss) on Foreign Currency Exchange | 1.34K -- | -11.18K -- | -7.83K -686.08% | -7.83K +29.95% | 2.42K +130.87% | 2.42K +130.87% | 1.29K -46.46% | -1.70K -170.21% | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 2.18M -- | 3.39M -- | 1.11M -49.14% | 2.27M -32.95% | 1.37M +23.63% | 2.93M +28.68% | 1.91M +39.57% | 3.43M +17.12% | 2.07M +7.96% | 3.98M +16.12% | 1.36M -34.06% | 1.94M -51.30% | 1.94M -- |
Pretax Income From Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.18M -- | -653.33K -- | -1.92M +11.73% | -- -- | -3.37M -75.75% | -3.37M -- |
Net Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 22.35M -- | 50.26M -- | 85.30M +281.60% | -- -- | 85.59M +0.35% | 85.59M -- |
Net Income Attributable to Owners of the Company | 30.19M -- | 123.05M -- | 31.55M +4.49% | 64.53M -47.56% | -76.30M -341.85% | -104.60M -262.10% | 33.80M +144.30% | 22.35M +121.37% | 50.26M +48.67% | 85.30M +281.60% | -47.23M -193.99% | 85.59M +0.35% | 85.59M -- |
Net Income Attributable to Common Stockholders | 30.19M -- | 123.05M -- | 31.55M +4.49% | 64.53M -47.56% | -76.30M -341.85% | -104.60M -262.10% | 33.80M +144.30% | 22.35M +121.37% | 50.26M +48.67% | 85.30M +281.60% | -47.23M -193.99% | 85.59M +0.35% | 85.59M -- |
Basic EPS | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.12 -- | -- -- | 2.89 -7.37% | 2.89 -- |
You can ask Aime
Did Abrdn Life Sciences Investors beat or miss consensus estimates last quarter?What guidance did Abrdn Life Sciences Investors's management provide for the next earnings period?What is the market's earnings forecast for Abrdn Life Sciences Investors next quarter?What is the revenue and EPS growth rate for Abrdn Life Sciences Investors year over year?What does Abrdn Life Sciences Investors do and what are its main business segments?What were the key takeaways from Abrdn Life Sciences Investors’s earnings call?What is Abrdn Life Sciences Investors's latest dividend and current dividend yield?What factors drove the changes in Abrdn Life Sciences Investors's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
